NAD+ Therapy in Alpharetta

What NAD+ is

NAD+, or nicotinamide adenine dinucleotide, is a coenzyme found in every living cell. We want to state this plainly, correcting how this page previously framed it: NAD+ is not a peptide. A peptide is a chain of amino acids; NAD+ is a small dinucleotide molecule that enzymes use to carry out oxidation-reduction reactions central to energy metabolism and cellular signaling. It occurs naturally in the body and is not itself a novel or synthetic compound, though it can be supplemented directly or supported indirectly through precursor molecules such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).

We keep this page under the peptide-therapy section of the site for navigation purposes only, because members search for it alongside peptide compounds. Chemically it belongs to a different category: coenzymes assist enzymes in catalyzing reactions, while peptides are built from amino acid chains. It is also more commonly encountered as a dietary supplement ingredient, through its precursors, than as an injectable drug candidate.

How it is thought to work

NAD+ is a required cofactor for enzymes involved in converting nutrients into cellular energy and for enzymes involved in DNA repair and cell signaling, including sirtuins and PARPs. NAD+ levels are understood to decline with age in some tissues, which is the rationale researchers give for studying whether restoring NAD+ levels through precursor supplementation might support aspects of metabolic or vascular health. That rationale is a hypothesis under active investigation, not an established outcome.

Because NAD+ itself does not cross cell membranes efficiently when taken orally, most human research has focused on precursor molecules the body can absorb and convert into NAD+ internally, principally nicotinamide riboside and nicotinamide mononucleotide. Research on "NAD+" in humans is therefore very often actually research on one of these precursors, and the route of administration, oral in nearly all published trials versus intravenous as sometimes marketed by wellness clinics, differs in ways not always made clear in consumer-facing material.

What the research shows

Human trials of NAD+ precursors are further along than most compounds discussed on this site, and we want to represent that fairly. A randomized, double-blind, placebo-controlled crossover trial in 24 healthy adults aged 55 to 79 found that six weeks of nicotinamide riboside (1,000 mg per day) raised NAD+-related metabolites in blood cells by roughly 60%, with good tolerability (Martens et al., 2018, Nature Communications). A short dose-escalation study in younger adults similarly found NAD+ roughly doubled in whole blood over 8 days of NR supplementation (Airhart et al., summarized in Dietary Supplementation With NAD+-Boosting Compounds, PMC).

The more important finding, and the one marketing pages tend to omit, is that raising NAD+ levels has not reliably translated into clear functional benefits. In the same 24-person trial, blood pressure and arterial stiffness showed modest improvement that did not survive statistical correction for multiple comparisons, and endothelial function, motor function, and exercise capacity did not change (Martens et al., 2018, Nature Communications). This is a consistent pattern across the small human trials conducted so far: elevating NAD+ is reproducible, but downstream benefits to energy, cognition, sleep, or performance remain inconsistent and unproven.

A separate short study in 12 older men found that three weeks of nicotinamide riboside doubled a related NAD+ metabolite in skeletal muscle, again confirming the precursor reaches target tissue, without establishing a functional outcome from that change (summarized in Dietary Supplementation With NAD+-Boosting Compounds, PMC). The pattern across these trials is consistent: the biochemistry is well replicated, and translation into a noticeable benefit for a healthy adult is not yet established.

What it is not

NAD+ is not a peptide, and it is not an FDA-approved treatment for aging, chronic fatigue, or any diagnosed condition. It is not a demonstrated weight-loss intervention, and no controlled human trial has established that NAD+ or its precursors produce the mental clarity, sleep, or mood benefits often attributed to it in wellness marketing. Where trials exist, they are small, generally under 30 participants, and short in duration, typically weeks rather than years.

It is also not a single, standardized product. "NAD+ therapy" as marketed can refer to oral precursor supplements, intravenous NAD+ infusions, or injectable precursor formulations, and these are not interchangeable. Intravenous NAD+ infusion protocols in particular have considerably less published human trial support than the oral precursor studies referenced above.

How Aeon approaches it

We describe NAD+ accurately: a coenzyme, not a peptide, with genuine human evidence that its precursors raise NAD+-related markers and comparatively weak evidence that this translates into noticeable functional change. If cellular energy, recovery, or healthy aging are your goals, a consultation can place NAD+ support in the context of your clinic lab results and broader hormone therapy picture, rather than treating a coenzyme as a cure-all.

We think it is worth naming that gap directly: raising a measurable blood marker is not the same as delivering a benefit you would notice, and we will walk through that distinction plainly before any recommendation is made.